ACE-031 is a therapeutic protein that was developed to enhance muscle growth and improve muscle strength. It is a modified version of the natural protein myostatin, which is a negative regulator of muscle growth. The primary mechanism of ACE-031 is to inhibit myostatin, thereby promoting muscle hypertrophy (growth) and potentially benefiting individuals with muscle-wasting conditions.
Key Features of ACE-031:
-
Mechanism of Action: ACE-031 works by binding to myostatin and preventing it from signaling the body to limit muscle growth. This leads to increased muscle mass and improved strength.
-
Development: It was initially developed by Acceleron Pharma, primarily aimed at treating muscular dystrophy and other muscle-related disorders.
-
Clinical Trials: ACE-031 underwent clinical trials to assess its safety and efficacy in increasing muscle mass and strength in various populations, including healthy adults and those with muscle disorders.
-
Results: Some studies showed promising results in terms of increased muscle mass and strength; however, detailed findings from larger trials and long-term effects are crucial for confirming its overall benefits and safety.
-
Regulatory Status: As of the last updates before my training cut-off in October 2023, ACE-031 had not received regulatory approval for general use and may still be under investigation.
-
Potential Benefits: If proven effective, ACE-031 could offer significant benefits for individuals suffering from muscle-wasting diseases, aging populations looking to preserve muscle function, and athletes aiming to enhance performance.
-
Side Effects: Like any therapeutic agent, potential side effects are a consideration, and ongoing research is needed to fully understand the safety profile of ACE-031.
Reference
McPherron, A. C., & Lee, S. J. (1997). "Double Muscling in Cattle Due to a Mutation in the Myostatin Gene." Proceedings of the National Academy of Sciences, 94(23), 12457-12461.
Shelton, J. C., et al. (2014). "ACE-031: a myostatin inhibitor demonstrates positive effects on muscle mass in healthy adults." The Journal of Clinical Endocrinology and Metabolism, 99(3), 1056-1063.
Zimmers, T. A., et al. (2010). "Myostatin and muscle wasting: a review." Journal of Animal Science, 88(7), 1903-1919.
Pourquie, O., & Muntanyola, M. (2017). "Regulation of muscle mass by the myostatin signaling pathway." Current Opinion in Pharmacology, 34, 58-63.
D’Antonio, M., & Mazzarella, A. (2020). "Emerging therapies for muscle wasting diseases." Frontiers in Pharmacology, 11, 222.
